Baird initiated coverage of Amylyx Pharmaceuticals with an Outperform rating and $37 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AMLX:
- Amylyx announces first patient dosed in ORION trial
- Mizuho lowers Amylyx price target to $27, calls ‘a top pick for 2024’
- These 3 Biotech Stocks Have Strong Upside Potential, Says Deutsche Bank
- Amylyx initiated with bullish view at Deutsche Bank, here’s why
- Amylyx announces data showing effect of AMX0035 on biomarkers in ALS